PharmaCorp Announces Closing of C$23 Million Bought Deal Public Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

CALGARY, Alberta, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. – PharmaCorp Rx Inc. (“PharmaCorp” or the “Company”) (TSXV: PCRX) is pleased to announce that it has closed its previously announced bought deal public offering co-led by Canaccord Genuity Corp. and Acumen Capital Finance Partners Limited, and including Raymond James Ltd., iA Private Wealth Inc., and Bloom Burton Securities Inc. (the “Underwriters”) pursuant to which the Underwriters purchased, on a bought deal basis, 54,855,000 units (the “Units”) in the capital of the Company at a price of C$0.42 per Unit (the “Offering Price”) for aggregate gross proceeds to the Company of approximately C$23.0 million, which includes the full exercise of the over-allotment option (the “Offering”).

Read more at globenewswire.com